Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Short Interest Update

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) saw a large decline in short interest during the month of December. As of December 15th, there was short interest totaling 11,067 shares, a decline of 45.3% from the November 30th total of 20,224 shares. Based on an average daily trading volume, of 33,204 shares, the short-interest ratio is presently 0.3 days. Approximately 0.2% of the shares of the stock are short sold. Approximately 0.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 33,204 shares, the short-interest ratio is presently 0.3 days.

Matinas Biopharma Trading Down 10.5%

Matinas Biopharma stock traded down $0.07 during midday trading on Friday, hitting $0.62. 53,644 shares of the stock were exchanged, compared to its average volume of 32,611. The stock has a market capitalization of $3.97 million, a price-to-earnings ratio of -0.18 and a beta of 1.33. The stock’s 50-day simple moving average is $1.02 and its 200 day simple moving average is $1.28. Matinas Biopharma has a fifty-two week low of $0.47 and a fifty-two week high of $3.09.

Matinas Biopharma (NYSEAMERICAN:MTNB) last posted its earnings results on Monday, November 10th. The company reported ($0.40) EPS for the quarter.

Matinas Biopharma Company Profile

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.